News

Starting the electrical therapy Optune Gio during radiation therapy and chemotherapy, rather than after it as indicated, did not extend survival in people with newly…

Weekly treatment with Context Therapeutics’ CTIM-76 was generally well tolerated and shrank tumors in some people with heavily pretreated platinum-resistant ovarian cancer, according…

Adults in the U.S. now have a new generic drug option — Bortezomib for Injection, an equivalent of the approved medication Velcade (bortezomib) —…

Nearly two-thirds of adults ages 80 and older with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), two related types of…

NeuExcell Therapeutics‘ investigational gene therapy, NXL-004, showed a potential survival benefit in a small group of people with recurrent malignant glioma in an…

Cellxlife signed a licensing agreement for a cell-based vaccine from Mayo Clinic that aims to teach the body’s immune system to recognize and…

Tecvayli (teclistamab) extended survival and kept disease under control longer than standard treatments in patients with relapsed or refractory multiple myeloma, meaning the…

Adding iadademstat, an experimental blood cancer drug, to standard of care treatment for acute myeloid leukemia (AML) appeared to be safe and effective in…

Treatment with Revolution Medicines‘ oral daraxonrasib more than doubled overall survival versus standard chemotherapy among adults with previously treated metastatic pancreatic cancer in…

Preliminary Phase 1 trial data show that uTREAT, Curasight’s experimental targeted cancer therapy, was safely delivered to aggressive solid brain tumors and reached estimated…